India, Oct. 23 -- Cumberland Pharmaceuticals Inc. (CPIX) reported results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban in patients with systemic sclerosis (SSc), with the study supporting the drug's safety and tolerability in this rare autoimmune disease.
CPIX closed Friday's regular trading at $8.49 up $0.01 or 0.12%. But in the after-hours trading, the stock dropped $1.49 or 17.55%.
The 12-month trial enrolled patients with either diffuse cutaneous systemic sclerosis (dcSSc) or systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). A total of 31 patients received ifetroban and 10 received placebo.
According to the company, ifetroban was generally well tolerated, with a safety profile consistent with pr...